NASDAQ:DICE DICE Therapeutics (DICE) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$47.55▼$47.5550-Day Range$46.62▼$47.5552-Week Range$15.08▼$47.90VolumeN/AAverage Volume1.03 million shsMarket Capitalization$2.27 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get DICE Therapeutics alerts: Email Address Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade About DICE Therapeutics Stock (NASDAQ:DICE)DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics. The company was founded in 2013 and is headquartered in South San Francisco, California.Read More Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade DICE Stock News HeadlinesAugust 31, 2024 | msn.comEli Lilly and Company (LLY): Jim Cramer's Go-To Stock For SuccessAugust 8, 2024 | msn.comLilly beefs up bowel disease drug portfolio with $3.2 billion Morphic dealSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.July 26, 2024 | forbes.comIs Eli Lilly Stock Headed Toward $1300 Levels?July 25, 2024 | yahoo.com"It's just a disgrace": Port Richmond residents demand city fix multiple craters on Aramingo AvenueApril 26, 2024 | finance.yahoo.comQ3 2024 Resmed Inc Earnings CallApril 3, 2024 | msn.comMinishoot' Adventures Hits Steam: A Bullet-Hell Bonanza with a Zelda TwistMarch 8, 2024 | seekingalpha.comVoyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver EasierSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.February 24, 2024 | msn.comStoke City player ratings vs Cardiff as Potters sink into relegation zoneJanuary 31, 2024 | es-us.finanzas.yahoo.comAbercrombie Announces Official Partnership With McLaren Racing, Features Race Car in Fifth Avenue StoreJanuary 30, 2024 | msn.com15 Best Acne Treatment Products For Teens in 2024January 3, 2024 | finance.yahoo.comStar Therapeutics Appoints Scott Robertson, MBA, as Chief Business Officer and Chief Financial OfficerDecember 30, 2023 | msn.comAltamira Therapeutics stock rises after it regains compliance with NasdaqNovember 29, 2023 | msn.comCan a Big Pharma Ever Be Worth $1 Trillion?November 4, 2023 | uk.finance.yahoo.comQ3 2023 Eli Lilly and Co Earnings CallOctober 25, 2023 | investing.comEli Lilly to buy Dice Therapeutics for $2.4 billionOctober 12, 2023 | es-us.finanzas.yahoo.comImmetas Therapeutics and GC Biopharma Announce Research Collaboration to Discover and Develop mRNA Therapeutics to Treat Autoimmune DiseasesSee More Headlines Receive DICE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DICE Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:DICE CUSIPN/A CIK1645569 Webwww.dicemolecules.com Phone650-566-1420FaxN/AEmployees71Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-83,890,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-22.01% Return on Assets-20.79% Debt Debt-to-Equity RatioN/A Current Ratio25.88 Quick Ratio32.44 Sales & Book Value Annual Sales$1.13 million Price / Sales2,008.50 Cash FlowN/A Price / Cash FlowN/A Book Value$10.86 per share Price / Book4.38Miscellaneous Outstanding Shares47,731,000Free Float45,392,000Market Cap$2.27 billion OptionableNot Optionable Beta1.03 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. J. Kevin Judice Ph.D. (Age 59)Founder, CEO & Director Comp: $840kMr. Scott RobertsonChief Bus. & Financial OfficerDr. Timothy Lu M.D. (Age 48)Ph.D., Chief Medical Officer Comp: $700kDr. John R. Jacobsen Ph.D. (Age 54)Chief Scientific Officer Ms. Mary Riley J.D.Gen. CounselMr. Venkat Thalladi Ph.D.Sr. VP of CMCMr. Paul FathereeSr. VP of Medicinal ChemistryMore ExecutivesKey CompetitorsBausch Health CompaniesNYSE:BHCCentessa PharmaceuticalsNASDAQ:CNTAPrevail TherapeuticsNASDAQ:PRVLScholar RockNASDAQ:SRRKMonte Rosa TherapeuticsNASDAQ:GLUEView All Competitors DICE Stock Analysis - Frequently Asked Questions How were DICE Therapeutics' earnings last quarter? DICE Therapeutics, Inc. (NASDAQ:DICE) announced its quarterly earnings data on Friday, November, 12th. The company reported ($2.30) EPS for the quarter, missing analysts' consensus estimates of ($0.53) by $1.77. When did DICE Therapeutics IPO? DICE Therapeutics (DICE) raised $160 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 10,000,000 shares at $15.00-$17.00 per share. This page (NASDAQ:DICE) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DICE Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DICE Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
